Last reviewed · How we verify
NCT07147166: FMTB Brij
Evaluating the Efficacy of Force Modulating Tissue Bridge Device in Preventing Hypertrophic Scars Following Gender-Affirming Mastectomy
NA trial testing Brijjit® BP100-6 and BP-75 in Gender Dysphoria in 78 participants. Currently enrolling.
1 June 2027
Quick facts
| Lead sponsor | University of California, San Francisco |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 78 |
| Start date | 3 February 2025 |
| Primary completion | 1 June 2027 |
| Estimated completion | 1 June 2027 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Brijjit® BP100-6 and BP-75
- Control: Standard of care and normal wound dressing
Conditions studied
- Gender Dysphoria — all drugs for Gender Dysphoria →
- Mastectomy — all drugs for Mastectomy →
- Hypertrophic Scar — all drugs for Hypertrophic Scar →
Sponsor
University of California, San Francisco
Who can join
19 and older, any sex, with Gender Dysphoria or Mastectomy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this randomized, prospective, interventional clinical trial is to evaluate the use of Brijjit® in reducing the incidence of hypertrophic scarring in individuals undergoing gender-affirming bilateral double incision mastectomies at a single-institution, single-surgeon site (Esther A. Kim, MD). Patients will serve as a self-control (one side of the chest receives intervention, the other serves as a control). Primary endpoints include scar appearance and quality. Secondary endpoints include patient perception of the scar using the Patient and Observer Scar Assessment Scale (POSAS). Participants will be taught how to apply Brijjit® at home if any units fall off before 6 weeks postop.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07147166
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Gender Dysphoria
Currently open trials in the same condition.
- NCT06969326 — Topical Estrogen: Brief Intervention to Improve Postoperative Experience for Transgender Men Undergoing Hysterectomy · Phase 3 · recruiting
- NCT06639776 — Sexual Functioning After Erection Prosthesis Placement in Post Phalloplasty Transgender Persons · recruiting
- NCT06639763 — Erectile Aid Use in Post-phalloplasty and Post-metoidioplasty Transgender Patients · recruiting
- NCT06351501 — Evaluation of the Effectiveness of Hormonal Treatment in Adolescents Suffering from Gender Dysphoria · Phase 3 · recruiting
- NCT05883553 — Epithesis Versus Prosthesis in Post-phalloplasty Transgender Patients. · NA · recruiting
Other University of California, San Francisco trials
Trials by the same sponsor.
- NCT05284773 — Screening for Acute Malnutrition · NA · withdrawn
- NCT04634851 — Video Home Visits for Dietary Counselling · NA · not yet recruiting
- NCT06065670 — Assessing Changes in Multi-parametric MRI in Patients With Acute Demyelinating Lesions Taking Clemastine Fumarate as a M · Phase 1, PHASE2 · not yet recruiting
- NCT07534098 — Intervention for Hearing Health Among Native Americans · NA · not yet recruiting
- NCT06960421 — Exercise-based Frailty Intervention in Lung Transplantation (XFIT) · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07147166 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of California, San Francisco
- Last refreshed: 22 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07147166.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing